Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCON: Relapse Escalation Treatment Trial in Optic Neuritis
2012-004807-10Phase 2Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of methylprednisolone in optic neuritis (ON), multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Mean RNFL thickness at week 16. Started Oct 2012; status: terminated.
02
Drugs
methylprednisolone
03
Conditions
optic neuritis (ON)multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2012-004807-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004807-10.